These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37365583)

  • 41. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.
    Elmén J; Lindow M; Silahtaroglu A; Bak M; Christensen M; Lind-Thomsen A; Hedtjärn M; Hansen JB; Hansen HF; Straarup EM; McCullagh K; Kearney P; Kauppinen S
    Nucleic Acids Res; 2008 Mar; 36(4):1153-62. PubMed ID: 18158304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PEI-complexed LNA antiseeds as miRNA inhibitors.
    Thomas M; Lange-Grünweller K; Dayyoub E; Bakowsky U; Weirauch U; Aigner A; Hartmann RK; Grünweller A
    RNA Biol; 2012 Aug; 9(8):1088-98. PubMed ID: 22894918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model.
    Hinkel R; Penzkofer D; Zühlke S; Fischer A; Husada W; Xu QF; Baloch E; van Rooij E; Zeiher AM; Kupatt C; Dimmeler S
    Circulation; 2013 Sep; 128(10):1066-75. PubMed ID: 23897866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. miR-20a inhibition using locked nucleic acid (LNA) technology and its effects on apoptosis of human macrophages infected by Toxoplasma gondii RH strain.
    Rezaei F; Daryani A; Sharifi M; Sarvi S; Jafari N; Pagheh AS; Hashemi N; Hejazi SH
    Microb Pathog; 2018 Aug; 121():269-276. PubMed ID: 29800695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.
    El Dika I; Lim HY; Yong WP; Lin CC; Yoon JH; Modiano M; Freilich B; Choi HJ; Chao TY; Kelley RK; Brown J; Knox J; Ryoo BY; Yau T; Abou-Alfa GK
    Oncologist; 2019 Jun; 24(6):747-e218. PubMed ID: 30598500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
    Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
    Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
    Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
    Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
    Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
    Creemers JHA; Pawlitzky I; Grosios K; Gileadi U; Middleton MR; Gerritsen WR; Mehra N; Rivoltini L; Walters I; Figdor CG; Ottevanger PB; de Vries IJM
    BMJ Open; 2021 Nov; 11(11):e050725. PubMed ID: 34848513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
    Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
    Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
    Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
    Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.
    Kim GM; Reid T; Shin SJ; Rha SY; Ahn JB; Lee SS; Chung HC
    Invest New Drugs; 2017 Dec; 35(6):773-781. PubMed ID: 28353123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.